Free Trial
NASDAQ:GTBP

GT Biopharma (GTBP) Stock Price, News & Analysis

$3.32
-0.21 (-5.95%)
(As of 10:00 AM ET)
Today's Range
$3.31
$3.57
50-Day Range
$3.00
$7.80
52-Week Range
$2.95
$16.11
Volume
36,160 shs
Average Volume
846,488 shs
Market Capitalization
$4.71 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$150.00

GT Biopharma MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
4,149.3% Upside
$150.00 Price Target
Short Interest
Healthy
0.21% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.27mentions of GT Biopharma in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.86 out of 5 stars

GTBP stock logo

About GT Biopharma Stock (NASDAQ:GTBP)

GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies. The company is developing GTB-3650, which is in preclinical studies that target CD33 on the surface of myeloid leukemias; and GTB-5550 that is in preclinical studies for treating patients with B7-H3 positive solid tumors. GT Biopharma, Inc. has a co-development partnership agreement with Altor BioScience Corporation for the clinical development of a 161533 (GTB-3550) TriKE fusion protein for cancer therapies; and a license agreement with the Regents of the University of Minnesota to develop and commercialize cancer therapies using TriKE technology. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in Brisbane, California.

GTBP Stock Price History

GTBP Stock News Headlines

Why Is GT Biopharma (GTBP) Stock Up 143% Today?
GT Biopharma, Inc. Common Stock (GTBP)
Raymond W. Urbanski's Net Worth
GT Biopharma reports Q1 results
Recap: GT Biopharma Q4 Earnings
GTBP Feb 2024 2.500 call
GT Biopharma, Inc. (GTBP)
GT Biopharma, Inc. Announces 1-for-30 Reverse Stock Split
GT Biopharma GAAP EPS of -$0.06
GT Biopharma Reports Third Quarter 2023 Financial Results
See More Headlines
Receive GTBP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for GT Biopharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/15/2024
Today
5/29/2024
Next Earnings (Estimated)
8/05/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:GTBP
Previous Symbol
OTCMKTS:OXISD
Fax
N/A
Employees
2
Year Founded
1965

Price Target and Rating

Average Stock Price Target
$150.00
High Stock Price Target
$150.00
Low Stock Price Target
$150.00
Potential Upside/Downside
+4,009.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-7,600,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$3.75 per share

Miscellaneous

Free Float
1,275,000
Market Cap
$5.18 million
Optionable
Optionable
Beta
0.65

Social Links

5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

  • Mr. Michael Martin Breen (Age 61)
    Interim CEO & Executive Chairman
    Comp: $1.04M
  • Mr. Manu Ohri (Age 69)
    CFO & Secretary
    Comp: $647.07k
  • Dr. Jeffrey S. Miller M.D.
    Consulting Chief Scientific Officer, Consulting Chief Medical Officer & Scientific Advisor

GTBP Stock Analysis - Frequently Asked Questions

Should I buy or sell GT Biopharma stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GT Biopharma in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" GTBP shares.
View GTBP analyst ratings
or view top-rated stocks.

What is GT Biopharma's stock price target for 2024?

1 brokers have issued twelve-month price objectives for GT Biopharma's shares. Their GTBP share price targets range from $150.00 to $150.00. On average, they anticipate the company's share price to reach $150.00 in the next year. This suggests a possible upside of 4,149.3% from the stock's current price.
View analysts price targets for GTBP
or view top-rated stocks among Wall Street analysts.

How have GTBP shares performed in 2024?

GT Biopharma's stock was trading at $7.65 at the start of the year. Since then, GTBP shares have decreased by 53.9% and is now trading at $3.53.
View the best growth stocks for 2024 here
.

Are investors shorting GT Biopharma?

GT Biopharma saw a decrease in short interest in May. As of May 15th, there was short interest totaling 2,700 shares, a decrease of 55.0% from the April 30th total of 6,000 shares. Based on an average daily trading volume, of 1,320,000 shares, the days-to-cover ratio is presently 0.0 days. Approximately 0.2% of the company's shares are sold short.
View GT Biopharma's Short Interest
.

When is GT Biopharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, August 5th 2024.
View our GTBP earnings forecast
.

How were GT Biopharma's earnings last quarter?

GT Biopharma, Inc. (NASDAQ:GTBP) issued its quarterly earnings results on Wednesday, May, 15th. The company reported ($2.12) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.70) by $0.58.

When did GT Biopharma's stock split?

Shares of GT Biopharma reverse split before market open on Monday, February 5th 2024. The 1-30 reverse split was announced on Monday, February 5th 2024. The number of shares owned by shareholders was adjusted after the market closes on Monday, February 5th 2024. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

How do I buy shares of GT Biopharma?

Shares of GTBP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:GTBP) was last updated on 5/29/2024 by MarketBeat.com Staff

From Our Partners